CXCL9 and neoplasm: Similar results were obtained with entolimod or imiquimod, two agonists of TLR5 and TLR7, respectively, which triggered a CD8 T-cell chemoattraction through an INFγ-CXCL9/10 pathway and colon or vaginal tumor growth delay [68,69].